Review
Oncology
Nishant Thakur, Muhammad Joan Ailia, Yosep Chong, Ok Ran Shin, Kwangil Yim
Summary: This study evaluated the prognostic significance, clinicopathological value, and relationship with epithelial-mesenchymal transition (EMT) of tumor budding (TB) in lung cancer. The results showed that high-grade TB was significantly associated with poor overall survival (OS) and disease-free survival (DFS), as well as clinicopathological characteristics and EMT markers.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Diogo J. Silva, Goncalo Miranda, Teresina Amaro, Matilde Salgado, Alexandra Mesquita
Summary: Tumor budding (TB) is a dynamic process associated with the epithelial-mesenchymal transition and has been proven to be a significant prognostic biomarker for colorectal cancer. This study aimed to investigate the clinical applicability and prognostic value of TB in patients with early breast cancer (EBC). The results showed a significant association between high TB score and aggressive clinicopathological features, as well as poor prognosis. The findings suggest that TB could serve as a valuable prognostic biomarker for EBC.
Article
Pharmacology & Pharmacy
Xiuyuan Zhang, Yiming Li, Pengbo Hu, Liang Xu, Hong Qiu
Summary: In this study, the joint role of epithelial-mesenchymal transition (EMT) and the immune microenvironment in gastric cancer (GC) progression was investigated. A model called EIRG_score was developed to predict prognosis and immunotherapeutic response. The results showed that the EIRG_score was significantly associated with prognosis, immune infiltration, gene mutation, chemotherapeutic drug sensitivity, and immunotherapy response.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Mitsunobu Oba, Yoshitsugu Nakanishi, Tomoko Mitsuhashi, Katsunori Sasaki, Kanako C. Hatanaka, Masako Sasaki, Ayae Nange, Asami Okumura, Mariko Hayashi, Yusuke Yoshida, Takeo Nitta, Takashi Ueno, Toru Yamada, Masato Ono, Shota Kuwabara, Keisuke Okamura, Takahiro Tsuchikawa, Toru Nakamura, Takehiro Noji, Toshimichi Asano, Kimitaka Tanaka, Kiyoshi Takayama, Yutaka Hatanaka, Satoshi Hirano
Summary: This study examined the association between CCR7 expression and clinicopathological features and EMT in EHCC. High-grade CCR7 expression was significantly correlated with aggressive tumor characteristics, low E-cadherin expression, and poor overall survival. Further experiments demonstrated that CCR7 promotes EHCC cell invasion and migration through induction of EMT, which can be inhibited by a CCR7 antagonist. These findings suggest that CCR7 may serve as a potential target for adjuvant therapy in EHCC.
Article
Multidisciplinary Sciences
Shaoqiu Zheng, Jing Luo, Shoucheng Xie, Shanming Lu, Qinghua Liu, Huanqin Xiao, Wenjuan Luo, Yanfang Huang, Kun Liu
Summary: Recent evidence suggests that cancer stem cells (CSCs) are the origin of cancers. This study investigated the relationship between tumor buds, which are hypothesized to represent epithelial-mesenchymal transition (EMT)-like CSCs, and EMT and CSC markers in cervical squamous cell carcinoma (CxSCC). The findings indicate that tumor buds in CxSCC may represent EMT-like CSCs in vivo.
Article
Oncology
Yujin Pan, Deyu Li, Jiuhui Yang, Ning Wang, Erwei Xiao, Lianyuan Tao, Xiangming Ding, Peichun Sun, Dongxiao Li
Summary: This study demonstrates the preferability of portal venous for CTC testing and the association of high PoV M-CTC count with increased risk of metastasis and shorter survival time in resectable PDAC patients. PoV CTC phenotype detection shows potential as a reliable and accurate tool for identifying high-risk PDAC patients for better management strategies.
FRONTIERS IN ONCOLOGY
(2021)
Article
Pathology
Han-Na Kim, Soo Yeon Lee, Baek-Hui Kim, Chung-Yeul Kim, Aeree Kim, Hayeon Kim
Summary: Tumor budding in gallbladder cancer has clinical and pathological implications, with high TB grades correlating with poorer survival outcomes, but not significantly associated with death or recurrence risk in multivariate analysis.
Review
Oncology
Kohei Okuyama, Keiji Suzuki, Souichi Yanamoto
Summary: This article summarizes the latest research on the relevance of tumor budding (TB) and partial epithelial-mesenchymal transition (p-EMT) as prognostic markers in the tumor microenvironment (TME) of head and neck squamous cell carcinoma (HNSCC). Understanding the mechanism of TB onset and the relationship between p-EMTs may facilitate the development of novel diagnostic and prognostic methods, and targeted therapies for the prevention of invasion and metastasis.
Article
Oncology
Julie Dardare, Andrea Witz, Margaux Betz, Aurelie Francois, Morgane Meras, Laureline Lamy, Aurelien Lambert, Stephanie Grandemange, Marie Husson, Marie Rouyer, Jessica Demange, Jean-Louis Merlin, Alexandre Harle, Pauline Gilson
Summary: This study investigates the role of DDB2 in pancreatic ductal adenocarcinoma (PDAC). The results show that lower expression of DDB2 is associated with shorter disease-free survival in PDAC patients. Overexpression of DDB2 can decrease cell migration and invasion, and increase sensitivity to certain chemotherapy drugs.
FRONTIERS IN ONCOLOGY
(2022)
Article
Immunology
Zhishang Meng, Yanzhu Chen, Wenyi Wu, Bin Yan, Lusi Zhang, Huihui Chen, Yongan Meng, Youling Liang, Xiaoxi Yao, Jing Luo
Summary: This study identified PRRX1 as a reliable TME-related biomarker that can predict survival and provide new insights into therapy for uveal melanoma (UM) patients. The results showed that increased PRRX1 expression is independently associated with poorer overall survival and metastasis-free survival in UM patients, and PRRX1 promotes malignant progression by facilitating epithelial-mesenchymal transition. These findings suggest that PRRX1 may be a potential target for UM therapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Mathematical & Computational Biology
Kaiyu Shen, Shuaiyi Ke, Binyu Chen, Tiantian Zhang, Hongtai Wang, Jianhui Lv, Wencang Gao
Summary: This study integrated single-cell RNA-sequencing and bulk sequencing data to analyze biomarkers for epithelial-mesenchymal transition in gastric cancer patients. A prognostic gene signature was established, which could be used for patient prognosis and tumor treatment.
MATHEMATICAL BIOSCIENCES AND ENGINEERING
(2023)
Review
Cell Biology
Tianyi Zhang, Yanxian Ren, Pengfei Yang, Jufang Wang, Heng Zhou
Summary: Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer with a high deposition of extracellular matrix (ECM) and poor prognosis. ECM proteins derived from tumor cells reduce the effectiveness of conventional cancer treatment and contribute to tumor progression and metastasis. Cancer-associated fibroblasts (CAFs) in the ECM are promising targets for novel anti-tumor interventions.
CELL DEATH & DISEASE
(2022)
Article
Oncology
Ana Pavlic, Emanuela Bostjancic, Rajko Kavalar, Bojan Ilijevec, Serena Bonin, Fabrizio Zanconati, Nina Zidar
Summary: This study investigates the involvement of epithelial-mesenchymal transition (EMT) in tumor budding (TB) and poorly differentiated clusters (PDCs) in colorectal cancer (CRC). The results suggest that both TB and PDCs are associated with partial EMT, but they exhibit discrete differences in morphology and expression of EMT-related markers.
JOURNAL OF PATHOLOGY
(2022)
Article
Oncology
Marie-Lucie Racu, Laetitia Lebrun, Andrea Alex Schiavo, Claude Van Campenhout, Sarah De Clercq, Lara Absil, Esmeralda Minguijon Perez, Calliope Maris, Christine Decaestecker, Isabelle Salmon, Nicky D'Haene
Summary: Pancreatic ductal adenocarcinoma (PDAC) has a low survival rate and its incidence is increasing over time. Understanding the molecular mechanisms behind metastasis and chemoresistance in PDAC is crucial, as these are the main causes of death in patients. SMAD4 is deactivated in half of PDAC cases and its loss is associated with worse overall survival and metastasis. SMAD4 is a key transducer in the TGF-beta pathway, which plays a role in epithelial-mesenchymal transition (EMT). EMT is a biological process where epithelial cells lose their characteristics and acquire a more mesenchymal phenotype, leading to increased motility. Recent studies suggest that cells may undergo intermediate states during EMT, known as epithelial-mesenchymal plasticity (EMP), which exhibit enhanced aggressiveness and more efficient metastasis. This review aims to summarize and analyze current knowledge on SMAD4 loss in PDAC patients and investigate its potential role in EMP, in order to better understand its function in PDAC carcinogenesis.
Review
Oncology
Muhammad Joan Ailia, Nishant Thakur, Yosep Chong, Kwangil Yim
Summary: This study investigated the role of tumor budding (TB) in gynecological cancers and found that TB is associated with poor survival outcomes. TB is related to epithelial-mesenchymal transition, microvessel density, and decreased hormone receptor expression. TB can be used as a poor prognostic marker for gynecologic cancers.
Article
Oncology
Leanne Li, Qiqun Zeng, Arjun Bhutkar, Jose A. Galvan, Eva Karamitopoulou, Daan Noordermeer, Mei-Wen Peng, Alessandra Piersigilli, Aurel Perren, Inti Zlobec, Hugh Robinson, M. Luisa Iruela-Arispe, Douglas Hanahan
Article
Oncology
Martin Wartenberg, Silvia Cibin, Inti Zlobec, Erik Vassella, Serenella Eppenberger-Castori, Luigi Terracciano, Micha David Eichmann, Mathias Worni, Beat Gloor, Aurel Perren, Eva Karamitopoulou
CLINICAL CANCER RESEARCH
(2018)
Review
Oncology
Eva Karamitopoulou
BRITISH JOURNAL OF CANCER
(2019)
Article
Biochemistry & Molecular Biology
Nikki K. Lytle, L. Paige Ferguson, Nirakar Rajbhandari, Kathryn Gilroy, Raymond G. Fox, Anagha Deshpande, Christian M. Schurch, Michael Hamilton, Neil Robertson, Pawan Noel, Martin Wartenberg, Inti Zlobec, Micha Eichmann, Jose A. Galvan, Eva Karamitopoulou, Tami Gilderman, Lourdes Adriana Esparza, Yutaka Shima, Philipp Spahn, Randall French, Nathan E. Lewis, Kathleen M. Fisch, Roman Sasik, Sara Brin Rosenthal, Marcie Kritzik, Daniel Von Hoff, Haiyong Han, Trey Ideker, Aniruddha J. Deshpande, Andrew M. Lowy, Peter D. Adams, Tannishtha Reya, Wei Lin
Review
Oncology
Eva Karamitopoulou, Beat Gloor
Editorial Material
Oncology
Eva Karamitopoulou
Article
Pathology
Eva Karamitopoulou, Irene Esposito, Inti Zlobec, Andrea Cacciato Insilla, Martin Wartenberg, David F. Schaeffer, Steve Kalloger, Stefano La Rosa, Christine Sempoux, Irene Ramos Centeno, Philipp Lohneis
Summary: Tumor budding has been identified as an independent prognostic factor in pancreatic ductal adenocarcinoma (PDAC) and its assessment methods showed moderate agreement levels between pathologists in a multicenter interobserver study. The pancytokeratin 10HPF method demonstrated acceptable levels of agreement and is recommended for tumor budding assessment in PDAC resection specimens. Implementing machine learning applications should be considered to improve interobserver agreement levels.
Article
Immunology
Hassan Sadozai, Animesh Acharjee, Serenella Eppenberger-Castori, Beat Gloor, Thomas Gruber, Mirjam Schenk, Eva Karamitopoulou
Summary: The study reveals a T cell-inflamed tumor microenvironment in long-term survivors of PDAC, with distinct immune characteristics compared to non-long-term survivors. The TME of long-term survivors helps determine disease prognosis and offers potential for precision medicine.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Hassan Sadozai, Animesh Acharjee, Thomas Gruber, Beat Gloor, Eva Karamitopoulou
Summary: This study investigated the immunological composition of tumors with high levels of tumor budding in PDAC cases, revealing that high grade of tumor budding is associated with diminished anti-tumor immunity. It was also found that high grade cases exhibited reduced densities of tumor-infiltrating leukocytes and different types of macrophages, indicating potential immune escape mechanisms that could contribute to disease progression.
Review
Oncology
Stefano Partelli, Francesco Sclafani, Sorin Traian Barbu, Marc Beishon, Pierluigi Bonomo, Graca Braz, Filippo de Braud, Thomas Brunner, Giulia Martina Cavestro, Mirjam Crul, Maria Die Trill, Piero Ferolla, Ken Herrmann, Eva Karamitopoulou, Cindy Neuzillet, Franco Orsi, Hanna Seppanen, Martina Torchio, Danila Valenti, Giulia Zamboni, Marc Zins, Alberto Costa, Philip Poortmans
Summary: The European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC) are guidelines written by experts from various disciplines in Europe to provide essential care throughout the patient journey. Pancreatic cancer presents challenges in diagnosis and treatment, with varying care standards across European countries. To achieve comprehensive cancer control, healthcare organisations must prioritize multidisciplinarity and patient-centered pathways as outlined in the ERQCC.
CANCER TREATMENT REVIEWS
(2021)
Article
Oncology
Eva Karamitopoulou, Andreas Andreou, Aurelie Pahud de Mortanges, Marianne Tinguely, Beat Gloor, Aurel Perren
CANCER IMMUNOLOGY RESEARCH
(2021)
Article
Oncology
Estefania Carrasco-Garcia, Lidia Lopez, Veronica Moncho-Amor, Fernando Carazo, Paula Aldaz, Manuel Collado, Donald Bell, Ayman Gaafar, Eva Karamitopoulou, Alexandar Tzankov, Manuel Hidalgo, Angel Rubio, Manuel Serrano, Charles H. Lawrie, Robin Lovell-Badge, Ander Matheu
Summary: The study shows that SOX9 plays a crucial role in the progression and metastasis of pancreatic cancer by regulating stemness and EMT processes. High levels of SOX9 are associated with metastases in clinical samples.
Editorial Material
Oncology
Eva Karamitopoulou
Article
Oncology
Eva Karamitopoulou, Andreas Andreou, Anna Silvia Wenning, Beat Gloor, Aurel Perren
Summary: This study links tumor mutational burden (TMB) levels with immune pathway activation and intratumoral immune responses in pancreatic adenocarcinoma (PDAC). The results show that TMB-high cases frequently belong to specific PDAC subsets with prolonged survival and display strong anti-tumor immune responses.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Multidisciplinary Sciences
Matteo Rossi Sebastiano, Chiara Pozzato, Maria Saliakoura, Zhang Yang, Ren-Wang Peng, Mirco Galie, Kevin Oberson, Hans-Uwe Simon, Evanthia Karamitopoulou, Georgia Konstantinidou